Brad Smith named as new CMMI director

HHS and CMS have announced Brad Smith will serve as the new director for the Centers for Medicare & Medicaid Innovation at CMS and senior advisor to HHS Secretary Alex Azar for value-based transformation. Smith was rumored to be the next pick to lead the agency’s centers following the departure of its former head Adam Boehler.

CMMI is the testing ground for CMS for pilot models and demonstration projects that aims to improve care, lower costs and support patient-centered practices across the healthcare system.

“Brad will help HHS and CMS continue and accelerate the value-based transformation work that we have begun under President Trump,” said Secretary Azar. "…Brad has impressive experience with innovative care delivery and paying for value, and he will help expand Administrator Verma’s and CMS’s efforts to ensure Medicare and Medicaid beneficiaries are getting better care, and better health, at a lower cost.”

Smith was most recently the chief operating officer of Anthem’s diversified business group. Anthem is the largest for-profit managed care business in the Blue Cross Blue Shield Association, with roughly 40 million members. Smith was also formerly CEO of Aspire Health, a home-based palliative care services company.

“Brad’s experience thinking outside-the-box to improve healthcare as a successful entrepreneur, along with his stellar academic and policy background, have prepared him well to lead CMMI and bring innovative solutions to our healthcare system’s most pressing challenges,” CMS Administrator Seema Verma said in a statement.

Former CMMI director Boehler left his position in July 2019 to lead the International Development Finance Corporation, a group that coordinates foreign aid and investment.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.